Lumos Hopes Its Oral Alternative to HGH Will Fuel Its Growth

Rick Hawkins, chairman and CEO of Lumos Pharma, discusses the company’s experimental oral therapy for pediatric growth hormone deficiency, how it works, and why it may be an attractive alternative to existing approaches.